For Life Sciences
Computational Gastroenterology Can Accelerate Clinical Trials
Iterative Scopes is developing powerful, AI-driven computer algorithms to support clinicians and biopharmaceutical companies as they seek to improve the processes for enrolling patients in clinical trials and assessing the drugs’ progress as they move through the clinical development trajectory.
Clinical trials for inflammatory bowel disease (IBD) are expensive, cumbersome and time-consuming, even by current biopharmaceutical R&D benchmarks. Manual centralized endoscopy readings are now standard in GI clinical trials, but these are highly dependent on readers’ training and levels of experience and therefore subjective. Manual endoscopy is also used to score disease severity for UC and CD patients, which GI specialists use to determine patient eligibility for clinical trials.
As a result, misclassification of disease severity is a challenge, as is the need for multiple endoscopies. Eligible patients often decide not to participate in clinical trials because of the burden of additional colonoscopies.
Automated Disease Severity Scoring
Iterative Scopes’s proprietary software automates interpretation of colonoscopy imaging in real time, enabling objective, standardized endoscopy readings.
These scores can help gastroenterologists more accurately identify appropriate patients for clinical trials and also eliminate the need for repeated endoscopies, which discourage patients from participating in clinical trials.
They also improve the accuracy of clinical endpoint readings, enabling more efficient and informative clinical trials.
How does it work?
Amy was diagnosed with Crohn's disease last year and is getting worse despite being on standard of care medicines. She has persistent stomach pain, diarrhea, and fatigue.
Amy's gastroenterologist wants to find the best treatment options for her. She is currently receiving steroids and an approved biologic.
Considering all the options…
One of the things that Amy's gastroenterologist has to decide is if she should try another biologic or if Amy is a good candidate for a clinical trial. Making this decision is a multifactorial and highly complex process that involves knowing Amy's entire clinical picture as well as the eligibility criteria of many trials.
The clinical trial
Clinical trials are conducted to verify efficacy and safety of new therapies and help the broader patient population live healthier lives. For Amy, inclusion in a trial can help her access novel treatments not yet available to the public.
Matching patients to the right trial is a complex process, complicated further by the need for accurate assessment of endoscopic presentation. We have developed algorithms to assist gastroenterologists in understanding disease severity. Our technology can tie together other clinical data points to reduce clinical and administrative burden in matching the right patient to the right trial.
We believe that our work will change the practice of Gastroenterology globally, empowering physicians to make more informed decisions for patients everywhere, just like Amy.
Novel Endpoint Development
Over the past decade, scientists have progressed from an anatomic to a histologic and now a genetic understanding of IBD. However, standard of care disease severity endpoints have remained largely unchanged. Iterative Scopes is actively building novel predictive models that improve characterization of disease severity and prediction of disease progression and individual therapeutic response.
For biopharmaceutical companies, the aim is to develop better tools for clinical trial recruitment and assessment of drug candidates. Ultimately, companies that use these tools will have competitive advantages in an increasingly crowded disease space.